Shots:
- The NMPA has approved Jascayd (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF); regulatory review is ongoing in Japan & the EU, with further filings planned
- Approval was based on P-III (FIBRONEER-IPF) assessing Jascayd (18 or 9mg, PO, BID) vs PBO in IPF pts, which met its 1EP of reduced FVC decline at 52wks., & showed favorable safety
- Jascayd, a selective PDE4B inhibitor, is approved by the US FDA in Oct 2025 for treating adults with IPF & is under review by the FDA (priority review) & NMPA for the treatment of adults with progressive pulmonary fibrosis
Ref: Boehringer Ingelheim| Image: Boehringer Ingelheim | Press Release
Related News:- Boehringer Ingelheim and AimedBio Partner to Advance an ADC Therapeutic in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
